Huapont Life Science Co., Ltd.
华邦健康
002004
Shenzhen Stock Exchange
Company Profile
The company continues to promote the "big health" development strategy, and the business structure is further clear. The core business, led by medicine and medical treatment, has maintained steady growth and high-quality development. Agricultural chemicals, new materials, tourism and other businesses have been separated and listed and operated independently. The company has been deeply engaged in the skin pharmaceutical industry for nearly 30 years, and is a leading enterprise in the field of skin clinical medicine and skin health in China. It has established an integrated business model of research, production and marketing from the front-end API to the back-end preparation. The company has a complete medical product echelon and extensive coverage, which can meet the comprehensive and multi-level needs of skin treatment of customers of all ages. While consolidating the leading position in the hospital market, the company actively uses its r&d and channel advantages to enhance the market share outside the hospital, and further expands its business scope to the medical beauty consumer market. The company's total operating 5 hospitals, comprehensive health care, rehabilitation, slow disease management, medical and other fields, the company in chongqing north forgiveness hospital as the core, give full play to the synergistic effect at home and abroad, and gradually establish a winbond health characteristic of medical service system, and is committed to become China's first-class private medical service brand.
Full description
I.Basic information Huapont Life Sciences Co., Ltd, founded in 1992, is a leading company in the field of skin clinical medicine and skin health in China. It was listed in Shenzhen Stock Exchange in 2004. After nearly 30 years of cultivation, the company has formed a major development direction of big health industry, business scope covers medicine, medical treatment, agricultural chemicals, new materials, tourism and other fields of development pattern. The company is currently the leading clinical skin drug service provider, pesticide leading enterprise, fine chemical intermediates and new materials industry leader in China. Headquartered in Liangjiang New Area of Chongqing, a state-level development zone, the company has more than 100 participating holding companies in more than 10 provinces and cities including Chongqing, Sichuan, Beijing and Zhejiang, as well as overseas countries such as the United States, Germany and Switzerland, with more than 12,000 employees worldwide, and its products are sold to 58 countries and regions around the world. At present, the company holds 3 listed companies (Kaisheng New Materials, Yingtai Biological, Lijiang Shares) and 1 listed company (Qinling Tourism). As a national high-tech enterprises, the company adhering to the "Great Wall health state of huaxia," business philosophy, attaches great importance to product development and technological innovation, drug therapy covers, tuberculosis, respiration, skin resistance to infection, tumor, ophthalmology, etc., the company currently has two kind of new drugs, the first copy products more than 20, article 13 rules with consistency evaluation of drugs, A number of products are listed in the national key new product plan, has obtained more than 420 patent authorization, a number of production processes and technologies in the leading position at home and abroad. In the future, the company will adhere to the pharmaceutical health as the core, and gradually improve the whole industry chain development model integrating API, preparation, cosmeceuticals, medical beauty and medical services, and is committed to building "Huabang" into the first brand of skin health in China.